07/08/2014 - 10:03am

Mylan announced the launch of telmisartan tablets USP, which is used to treat hypertension.

07/07/2014 - 6:31pm

Sandoz announced the launch of valsartan tablets, an authorized generic version of Diovan tablets which is used for the treatment of high blood pressure.

07/07/2014 - 1:23pm

According to a report from the American Academy of Family Physicians, the Advisory Committee on Immunization Practices for the Centers for Disease Control and Prevention voted unanimously to recommend that healthy children between the ages of 2 years and 8 years be inoculated with a live attenuated influenza vaccine like FluMist, as opposed to the traditional flu shot. 

07/03/2014 - 12:48pm

The Food and Drug Administration on Tuesday made available a draft of its strategic priorities over the next four years for public comment.

07/03/2014 - 11:36am

Impax Labs on Wednesday announced that it has acquired from Actavis two generic products for cash consideration. Financial terms of the agreement were not disclosed.

07/03/2014 - 10:38am

A study published Tuesday online by the journal Pediatrics found that the protective benefits provided by vaccines for children significantly outweighed the extremely rare possiblity of an adverse event.

07/02/2014 - 2:17pm

Express Scripts has taken as many as 1,000 active ingredients widely used by compounding pharmacies off of their coverage list, according to a Wall Street Journal report published Tuesday. 

07/02/2014 - 2:05pm

Upsher-Smith Laboratories on Wednesday announced the launch of testosterone gel (1%), the generic of Vogelxo (testosterone) gel 1%, for topical use. Newly approved by the Food and Drug Administration, it is the first and only available generic testosterone replacement therapy available in three configurations, the company stated.

07/02/2014 - 12:33pm

Actavis on Wednesday announced that its subsidiary Forest Labs has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug, following approval.